

## Mandatory notification of trade and disclosure of large shareholding

Oslo, Norway, 29 April 2026: Reference is made to the stock exchange announcement by IDEX Biometrics ASA ("**IDEX**" or the "**Company**") on 29 April 2026 regarding the completion of a private placement of new shares in the Company with gross proceeds in the amount of approximately NOK 80 million (the "**Private Placement**") where the Company allocated 9,696,969 new ordinary shares in the Company ("**Offer Shares**") each at a subscription price of NOK 8.25 per Offer Share (the "**Subscription Price**").

Information about allocation in the Private Placement to primary insiders and close associates of primary insiders pursuant to the Market Abuse Regulation article 19 is attached with this notice.

Reference is further made to the stock exchange announcement made by the Company on 29 April 2026 regarding the settlement of the Private Placement through a share lending agreement entered into between the Company, the Manager and Anders Storbråten, the CEO of the Company (the "**Share Lender**") (the "**Share Lending Agreement**"). The Share Lender has today, pursuant to the Share Lending Agreement and pursuant to the conditions for the Private Placement being fulfilled, lent out 9,696,969 ordinary shares in order to facilitate DVP settlement of the Private Placement (the "**Share Lending**"). Please see the attached form of notification pursuant to the Market Abuse Regulation article 19.

Following the Share Lending, the Share Lender's holding of 12,335,515 ordinary shares in the Company (of which 10,458,883 ordinary shares is held directly, and 1,876,632 shares is held through Pinchcliffe AS), will be reduced to 2,638,546 ordinary shares in the Company, constituting respectively 18.97% and 4.06% of the share capital and votes outstanding in the Company. Consequently, the Share Lender's total registered holding of shares has fallen below the 15%, 10% and 5% thresholds pursuant to section 4-2 (1) of the Norwegian Securities Trading Act. The above calculations have been made based on a total of 65,011,963 outstanding shares in the Company currently registered in the Norwegian Register of Business Enterprises (the "**NRBE**").

The Share Lending is made solely for settlement purposes and will be returned upon registration of the share capital increase for issuance of the Offer Shares in Tranche 1 of the Private Placement resolved by the Company's board on 28 April 2026, and the Offer Shares in Tranche 2 to be resolved issued by the Board after registration of the share capital increase pertaining to the Tranche 1 Offer Shares in the NRBE, pursuant to the board authorization granted by the Company's extraordinary general meetings on 27 March 2026, and will consequently not reduce the Share Lender's ownership interest in the Company.



**PRESS RELEASE**  
29 April 2026 07:48:00 CEST

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation Article 19 and section 4-2 and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Anders Storbråten, CEO and CFO  
Tel: +47 416 38 582  
E-mail: [ir@idexbiometrics.com](mailto:ir@idexbiometrics.com)

#### **About IDEX Biometrics ASA**

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

#### **Attachments**

[2 1 20260428 MAR Share Lending And Pre Commitment Primary Insider Notification \(14478359 1\) 2](#)